anastrozole has been researched along with Lymph Node Metastasis in 27 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 9.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)." | 9.14 | Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C, 2010) |
| "3 months, women who received anastrozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer, or distant metastasis) compared with women who received no further treatment (n = 469; hazard ratio = 0." | 9.12 | Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. ( Dadak, C; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kubista, E; Kwasny, W; Mlineritsch, B; Renner, K; Rücklinger, E; Samonigg, H; Schmid, M; Stierer, M; Tausch, C, 2007) |
| "Anastrozole, an orally active, nonsteroidal aromatase inhibitor, was evaluated in a randomized, double-blind, single-center study to determine its efficacy as neoadjuvant therapy in postmenopausal women with newly diagnosed, estrogen receptor-rich, locally advanced or large (>3 cm), operable breast cancers." | 9.09 | The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. ( Bellamy, C; Dixon, JM; Hoctin-Boes, G; Miller, WR; Renshaw, L; Stuart, M, 2000) |
| "We report the case of a patient in which S-1 plus anastrozole was administered as first-line chemotherapy for Stage IV breast cancer with skin invasion, multiple lymph node metastasis, and lymphangitis carcinomatosis." | 7.85 | [A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy]. ( Akami, T; Hatakeyama, T; Matsumura, A; Mugitani, T; Ogino, S; Okano, S; Sakai, T, 2017) |
| "For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice." | 5.32 | [Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004) |
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 5.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)." | 5.14 | Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C, 2010) |
| "Third-generation nonsteroidal aromatase inhibitors (AIs), letrozole and anastrozole, are superior to tamoxifen as initial therapy for early breast cancer but have not been directly compared in a head-to-head adjuvant trial." | 5.12 | A decade of letrozole: FACE. ( O'Shaughnessy, J, 2007) |
| "3 months, women who received anastrozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer, or distant metastasis) compared with women who received no further treatment (n = 469; hazard ratio = 0." | 5.12 | Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. ( Dadak, C; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kubista, E; Kwasny, W; Mlineritsch, B; Renner, K; Rücklinger, E; Samonigg, H; Schmid, M; Stierer, M; Tausch, C, 2007) |
| "Anastrozole, an orally active, nonsteroidal aromatase inhibitor, was evaluated in a randomized, double-blind, single-center study to determine its efficacy as neoadjuvant therapy in postmenopausal women with newly diagnosed, estrogen receptor-rich, locally advanced or large (>3 cm), operable breast cancers." | 5.09 | The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. ( Bellamy, C; Dixon, JM; Hoctin-Boes, G; Miller, WR; Renshaw, L; Stuart, M, 2000) |
| "We report the case of a patient in which S-1 plus anastrozole was administered as first-line chemotherapy for Stage IV breast cancer with skin invasion, multiple lymph node metastasis, and lymphangitis carcinomatosis." | 3.85 | [A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy]. ( Akami, T; Hatakeyama, T; Matsumura, A; Mugitani, T; Ogino, S; Okano, S; Sakai, T, 2017) |
| "Tumors from 228 postmenopausal women with confirmed ER+ stage 2 and 3 breast cancers in the P024 neoadjuvant endocrine therapy trial, which compared letrozole and tamoxifen for 4 months before surgery, were analyzed for posttreatment ER status, Ki67 proliferation index, histological grade, pathological tumor size, node status, and treatment response." | 3.74 | Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. ( A'Hern, R; Bhatnagar, AS; Chaudri Ross, HA; Dowsett, M; Eiermann, W; Ellis, MJ; Evans, DB; Luo, J; Miller, WR; Smith, I; Tao, Y; von Kameke, A, 2008) |
| "The steroidal aromatase inactivator exemestane has demonstrated activity after prior failure of non-steroidal aromatase inhibitors (including third-generation inhibitors letrozole and anastrozole) in postmenopausal women with advanced breast cancer." | 3.73 | Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. ( Bertelli, G; Bertolotti, L; Castiglione, F; Del Mastro, L; Fusco, O; Garrone, O; Leonard, RC; Merlano, M; Occelli, M; Pepi, F, 2005) |
| "We present a case of breast carcinoma in the axillary ectopic mammary gland and summarize the clinical features of 94 cases, including ours, in Japan." | 2.47 | A case of ectopic breast cancer with a literature review. ( Kameda, N; Nihon-Yanagi, Y; Okazumi, S; Ueda, T, 2011) |
| "The treatment of node-positive breast cancer has improved dramatically in the last 3 decades." | 2.43 | Adjuvant therapy for patients who have node-positive breast cancer. ( Chu, QD; Li, BD; McDonald, JC, 2006) |
| "106 patients treated for breast cancer at Southampton University Hospital with PHT without surgery were identified (Mean age 84." | 1.42 | Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma. ( Cutress, RI; Layfield, DM; Mohamud, M; Odofin, O; Royle, GT; Walsh, C, 2015) |
| "For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice." | 1.32 | [Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004) |
| "Anastrozole has excellent antitumor activity in postmenopausal women, but no data exist on its efficacy in men." | 1.31 | Efficacy of anastrozole in male breast cancer. ( Buzdar, AU; Giordano, SH; Hortobagyi, GN; Valero, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (70.37) | 29.6817 |
| 2010's | 8 (29.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mugitani, T | 1 |
| Hatakeyama, T | 1 |
| Sakai, T | 1 |
| Matsumura, A | 1 |
| Ogino, S | 1 |
| Akami, T | 1 |
| Okano, S | 1 |
| Layfield, DM | 1 |
| Mohamud, M | 1 |
| Odofin, O | 1 |
| Walsh, C | 1 |
| Royle, GT | 1 |
| Cutress, RI | 1 |
| Kusama, H | 1 |
| Okishiro, M | 1 |
| Ishida, T | 1 |
| Sato, Y | 1 |
| Morimoto, Y | 1 |
| Matsushita, K | 1 |
| Hashimoto, T | 1 |
| Kimura, K | 1 |
| Katsura, Y | 1 |
| Nitta, K | 1 |
| Kagawa, Y | 1 |
| Takeno, A | 1 |
| Sakisaka, H | 1 |
| Nakahira, S | 1 |
| Taniguchi, K | 1 |
| Egawa, C | 1 |
| Takeda, Y | 1 |
| Kato, T | 1 |
| Tamura, S | 1 |
| Takatsuka, Y | 1 |
| Oku, K | 1 |
| Goto, T | 1 |
| Nagano, T | 1 |
| Nakatsuka, S | 1 |
| Buus, R | 1 |
| Sestak, I | 1 |
| Kronenwett, R | 1 |
| Denkert, C | 1 |
| Dubsky, P | 1 |
| Krappmann, K | 1 |
| Scheer, M | 1 |
| Petry, C | 1 |
| Cuzick, J | 1 |
| Dowsett, M | 4 |
| Smith, I | 2 |
| Yardley, D | 1 |
| Burris, H | 1 |
| De Boer, R | 1 |
| Amadori, D | 1 |
| McIntyre, K | 1 |
| Ejlertsen, B | 1 |
| Gnant, M | 2 |
| Jonat, W | 2 |
| Pritchard, KI | 1 |
| Hart, L | 1 |
| Poggio, S | 1 |
| Comarella, L | 1 |
| Salomon, H | 1 |
| Wamil, B | 1 |
| O'Shaughnessy, J | 2 |
| Nagykálnai, T | 1 |
| Ellis, MJ | 1 |
| Tao, Y | 1 |
| Luo, J | 1 |
| A'Hern, R | 1 |
| Evans, DB | 1 |
| Bhatnagar, AS | 1 |
| Chaudri Ross, HA | 1 |
| von Kameke, A | 1 |
| Miller, WR | 3 |
| Eiermann, W | 1 |
| Murata, T | 1 |
| Yoshino, H | 1 |
| Bandou, H | 1 |
| Morita, K | 1 |
| Kurokawa, M | 1 |
| Inaki, N | 1 |
| Kotake, M | 1 |
| Kadoya, S | 1 |
| Yamamoto, M | 1 |
| Takayanagi, T | 1 |
| Yamada, T | 1 |
| Sakurai, T | 2 |
| Umemura, T | 1 |
| Jinta, E | 1 |
| Suzuma, T | 1 |
| Yoshimura, G | 1 |
| Shimizu, S | 1 |
| Nihon-Yanagi, Y | 1 |
| Ueda, T | 1 |
| Kameda, N | 1 |
| Okazumi, S | 1 |
| Cristofanilli, M | 1 |
| Valero, V | 2 |
| Mangalik, A | 1 |
| Royce, M | 1 |
| Rabinowitz, I | 1 |
| Arena, FP | 1 |
| Kroener, JF | 1 |
| Curcio, E | 1 |
| Watkins, C | 1 |
| Bacus, S | 1 |
| Cora, EM | 1 |
| Anderson, E | 1 |
| Magill, PJ | 1 |
| Recchia, F | 1 |
| Candeloro, G | 1 |
| Necozione, S | 1 |
| Desideri, G | 1 |
| Recchia, CO | 1 |
| Piazze, J | 1 |
| Rea, S | 1 |
| Mori, K | 1 |
| Chiba, N | 1 |
| Yamamoto, Y | 1 |
| Yonekawa, H | 1 |
| Miyoshi, K | 1 |
| Ohtsuka, S | 1 |
| Inagaki, M | 1 |
| Ohsaki, T | 1 |
| Fuchimoto, S | 1 |
| Yumura, M | 1 |
| Nakagawa, T | 1 |
| Dixon, JM | 2 |
| Jackson, J | 1 |
| Hills, M | 1 |
| Renshaw, L | 2 |
| Cameron, DA | 1 |
| Anderson, TJ | 1 |
| Rai, Y | 1 |
| Ando, M | 1 |
| Sagara, Y | 2 |
| Takahama, T | 1 |
| Matsuyama, Y | 1 |
| Ooi, Y | 1 |
| Bertelli, G | 1 |
| Garrone, O | 1 |
| Merlano, M | 1 |
| Occelli, M | 1 |
| Bertolotti, L | 1 |
| Castiglione, F | 1 |
| Pepi, F | 1 |
| Fusco, O | 1 |
| Del Mastro, L | 1 |
| Leonard, RC | 1 |
| Giordano, SH | 2 |
| Hortobagyi, GN | 2 |
| Carlini, P | 1 |
| Papaldo, P | 1 |
| Fabi, A | 1 |
| Felici, A | 1 |
| Ruggeri, EM | 1 |
| Milella, M | 1 |
| Ciccarese, M | 1 |
| Nuzzo, C | 1 |
| Cognetti, F | 1 |
| Ferretti, G | 1 |
| Chu, QD | 1 |
| McDonald, JC | 1 |
| Li, BD | 1 |
| Margolis, R | 1 |
| Budd, GT | 1 |
| Singh, AD | 1 |
| Mundhenke, C | 1 |
| Jakesz, R | 1 |
| Greil, R | 1 |
| Schmid, M | 1 |
| Kwasny, W | 1 |
| Kubista, E | 1 |
| Mlineritsch, B | 1 |
| Tausch, C | 1 |
| Stierer, M | 1 |
| Hofbauer, F | 1 |
| Renner, K | 1 |
| Dadak, C | 1 |
| Rücklinger, E | 1 |
| Samonigg, H | 1 |
| Bellamy, C | 1 |
| Stuart, M | 1 |
| Hoctin-Boes, G | 1 |
| Buzdar, AU | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Assessment of Disease Progression in Primary Breast Cancer Patients Undergoing EndoPredict® Gene Expression Testing - a Care Research Study[NCT03503799] | 1,191 participants (Actual) | Observational [Patient Registry] | 2018-07-17 | Active, not recruiting | |||
| A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertu[NCT03272477] | Phase 2 | 257 participants (Actual) | Interventional | 2017-10-05 | Active, not recruiting | ||
| Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study[NCT01016665] | 71 participants (Actual) | Interventional | 2005-04-30 | Completed | |||
| Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study.[NCT05163106] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-12-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for anastrozole and Lymph Node Metastasis
| Article | Year |
|---|---|
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2008 |
A case of ectopic breast cancer with a literature review.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carc | 2011 |
Adjuvant therapy for patients who have node-positive breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatas | 2006 |
7 trials available for anastrozole and Lymph Node Metastasis
| Article | Year |
|---|---|
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2017 |
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2010 |
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Double-Bli | 2004 |
The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozo | 2007 |
A decade of letrozole: FACE.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase | 2007 |
The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Dr | 2000 |
17 other studies available for anastrozole and Lymph Node Metastasis
| Article | Year |
|---|---|
[A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy].
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Drug Co | 2017 |
Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Axilla; Biopsy, Large-Core Ne | 2015 |
[A case of hyoid bone metastasis from breast cancer].
Topics: Aged; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols | 2014 |
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Follo | 2016 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
[A case of metastatic breast cancer resistant to anastrozole treatment responding to high-dose toremifene].
Topics: Anastrozole; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lymph Node Excision; Lymph | 2009 |
[Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2009 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2004 |
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; C | 2011 |
[A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carci | 2002 |
[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2004 |
[Neoadjuvant endocrine therapy with anastrozole significantly downstaged an elderly breast cancer woman with locally-advanced breast cancer which became operable].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Duc | 2005 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Leuprolide acetate plus aromatase inhibition for male breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2006 |
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Ind | 2006 |
Unusual macular degeneration following breast cancer.
Topics: Adenocarcinoma; Anastrozole; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Choroid Neoplas | 2007 |
Efficacy of anastrozole in male breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Ne | 2002 |